![Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/053990c1-6dbb-4a9b-b3a9-8123ab8ba8de/gr1_lrg.jpg)
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology
![Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - The Lancet Neurology Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/e42bfe7e-16bb-42be-9202-b81aa80fe74c/gr1.jpg)
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - The Lancet Neurology
![Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0967586814006195-gr7.jpg)
Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect
![Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/dad580fb-1278-4fc7-ae5b-1f405d46bc90/gr1.gif)
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology
![Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis | Rheumatology & Autoimmunity Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis | Rheumatology & Autoimmunity](https://mednexus.org/cms/asset/2e124bc9-189a-462e-9d1c-75b12ebc32a4/rai212059-gra-0001.png)